BACAP-2: Anatomical-Clinical Base of Adenocarcinoma Pancreatic

Sponsor

University Hospital, Toulouse (Other)

Overall Status

Recruiting

CT.gov ID

NCT06128343

Collaborator

(none)

1,500

Enrollment

Locations

135.4

Anticipated Duration (Months)

187.5

Patients Per Site

1.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.

Condition or Disease	Intervention/Treatment	Phase
Adenocarcinoma Carcinoma Neoplasms	Other: collection of biological samples

Detailed Description

Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.

The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy).

The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on:

the development of new diagnostic tools,
understanding the development of tumors of the pancreas
the development of new therapeutic targets
understanding the response to chemotherapy…

Study Design

Study Type:

Observational

Anticipated Enrollment :

1500 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Anatomical-Clinical Base of Adenocarcinoma Pancreatic

Actual Study Start Date :

Nov 16, 2023

Anticipated Primary Completion Date :

Jan 31, 2035

Anticipated Study Completion Date :

Feb 28, 2035

Outcome Measures

Primary Outcome Measures

Enrichment of prospective BACAP collection [5 years]
This collection is coming to enrich the prospective BACAP collection of fresh tumor tissue and/or fixed from the micro-biopsy under endoscopic ultrasound

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 120 Years

Sexes Eligible for Study:

All

Inclusion Criteria:

Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or
Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or
Patient with pancreatic adenocarcinoma proven histologically and/or cytologically

Exclusion Criteria:

Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
Pregnant or breastfeeding patient

Contacts and Locations

Locations

	Site	City	Country	Postal Code
1	Haut-Lévêque Hospital	Bordeaux	France	33604
2	Béthune hospital center	Béthune	France	62408
3	Huriez Hospital	Lille	France	59037
4	Jean Mermoz private hosptila	Lyon	France	69008
5	Saint Eloi Hospital	Montpellier	France	34295
6	Regional Cancer Center From Montpellier	Montpellier	France	34298
7	PAU hospital	Pau	France	6400
8	Rangueil hospital	Toulouse	France	31059